Cardio Diagnostics 2025 Q2 Earnings Sustained Losses Amid Revenue Decline

Cardio Diagnostics reported its fiscal 2025 Q2 earnings on August 15, 2025. The results fell short of profitability, with a narrowed but still significant loss per share and a modest revenue decline. While the company provided no formal guidance, it outlined a forward-looking strategy focused on R&D expansion and new product approvals.

Revenue
Cardio Diagnostics reported total revenue of $7,475 for Q2 2025, representing a 5.0% decline from $7,870 in the same period of the previous year. The entire revenue came from product test sales, as the total segment revenue was also reported at $7,475, indicating a single revenue-generating segment.

Earnings/Net Income
The company narrowed its loss per share to $0.97 in Q2 2025 from $1.71 in Q2 2024, a 43.3% improvement. However, the net loss expanded to $1.68 million, up 30.7% from the $1.29 million loss in the prior-year period. Cardio Diagnostics has recorded losses in this quarter for four consecutive years, underscoring ongoing financial challenges. The performance reflects a mixed financial picture with improved per-share losses but a widening total loss.

Price Action
The stock price of Cardio Diagnostics rose 4.22% on the latest trading day and 3.95% during the most recent full trading week. However, the month-to-date performance was negative, with a 9.76% decline.

Post-Earnings Price Action Review
Despite the mixed earnings results, a post-earnings investment strategy involving a 30-day holding period following the Q2 report resulted in a disastrous return of -95.99%, significantly underperforming the benchmark by 161.50%. The strategy was marked by a maximum drawdown of 0.00%, a Sharpe ratio of -0.32, and volatility of 218.71%, signaling an extremely high-risk approach with poor risk-adjusted returns.

CEO Commentary
Cardio Diagnostics’ CEO reaffirmed the company’s commitment to advancing cardiovascular innovation, highlighting the recent market approval of RunFlow® as a key milestone. Despite a Q2 2025 net loss of $1.68 million and an EPS of -$0.97, the CEO expressed cautious optimism about long-term growth, particularly in α-Ketoglutarate-based heart regeneration therapies and AI-driven diagnostics. Strategic investments in R&D and structural heart disease models are expected to bolster the company’s market position in the coming years.

Guidance
No explicit revenue or EPS guidance was provided. The CEO outlined a forward-looking strategy emphasizing the scaling of clinical trials, expanding AI diagnostics partnerships, and accelerating product approvals. The company plans continued R&D investment and the utilization of its CNAS-certified infrastructure for high-quality preclinical validation, with a focus on improving profitability through the commercialization of innovative cardiovascular solutions.

Additional News
Recent non-earnings-related news includes the launch of the Shanghai Daily’s digital subscription offerings, which provide real-time access to downloadable PDF editions, unlimited online content, and breaking news updates. Subscribers can choose from various digital and print packages, with no refunds offered for digital subscriptions. The online edition does not include physical newspapers, but it enhances accessibility for global readers seeking real-time Chinese market insights and news.